RAIR By Faye Higbee
“WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.” World Health Organization
Remdesivir is a highly toxic drug that medical officials advocate in the fight against Covid. But what is it, and why do the same officials ferociously defend it when there are known side effects that are deadly? The FDA approved it under the name Veklury for IVs in non-hospitalized outpatient treatment on January 27, 2022. They also terminated approval of two monoclonal antibody drugs, saying they “didn’t work” for the Omicron variant. Those two drugs had known life-extending properties for Covid patients. Let’s have a look at the controversy and why there may be more to this than meets the eye.
Failed Drug
Remdesivir was developed in 2009 by Gilead Sciences to treat hepatitis C and respiratory syncytial virus (RSV), but it didn’t work against those diseases. So they “repurposed” it for Ebola and Marburg viruses in 2014. It wasn’t effective in stopping the replication of those viruses either. Now it has once again been “repurposed” for Covid. But the narrative of the NIH is that it does stop the replication of the SARS-Cov-2 virus. It is not recommended for treating Covid patients, but that hasn’t stopped the ‘powers that be.’
